Roger Gunn

Roger Gunn, PhD, is an international expert in imaging and drug development. He has discovered, developed and translated imaging techniques to measure biological processes for drug development and they are now central to biomarker strategies of pharmaceutical companies. In his current role as chief science officer at Xing Imaging, he is heading the research and development of new biomarkers and analytics and leading the design, analysis and delivery of clinical imaging trials for pharmaceutical companies. He is also Emeritus Professor of Molecular Neuroimaging at Imperial College and founder of the analytics software company MIAKAT Ltd. Dr. Gunn has published over 200 peer reviewed papers in the field of imaging, neuroscience and drug development with an H-index of 78 and has delivered over 80 invited lectures. His career has involved positions on research councils, consultancy to pharmaceutical companies and the training and mentoring of PhD students and clinical research fellows.